Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989，NSC-2260804

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Cited by 73 Publications

Nature, 2016, 539(7629):437-442

PubMed: 27642729 ( click the link to review the publication )

Cell, 2019, 176(6):1379-1392

PubMed: 30773315 ( click the link to review the publication )

Nature, 2016, 532(7599):389-93

PubMed: 27064903 ( click the link to review the publication )

Nat Genet, 2014, 46(4):364-70

PubMed: 24584072 ( click the link to review the publication )

Cancer Cell, 2011, 19(6):792-804

PubMed: 21620777 ( click the link to review the publication )

Cell Res, 2012, 22(6):1003-21

PubMed: 22430150 ( click the link to review the publication )

J Hepatol, 2015, 10.1016/j.jhep.2015.11.011

PubMed: 26592953 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI124590

PubMed: 30830877 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

Autophagy, 2015, 10.1080/15548627.2015.1023982

PubMed: 25906440 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(22):7116-26

PubMed: 21976531 ( click the link to review the publication )

Leukemia, 2019, 33(1):181-190

PubMed: 29884903 ( click the link to review the publication )
Proc Natl Acad Sci USA, 2013, 110(33):13588-93

PubMed: 23898208 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(22):6635-47

PubMed: 25252916 ( click the link to review the publication )

Cancer Res, 2013, 73(17):5449-58

PubMed: 23832664 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.01.014

PubMed: 25660019 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.23525

PubMed: 28524818 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

Int J Cancer, 2018, 142(1):202-213

PubMed: 28905990 ( click the link to review the publication )

J Hematol Oncol, 2013, 6:18

PubMed: 23415012 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.150

PubMed: 27132509 ( click the link to review the publication )

Oncogene, 2015, 34(2):263-8

PubMed: ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.226

PubMed: 26165839 ( click the link to review the publication )
Oncogene, 2014, 10.1038/onc.2014.355

PubMed: 25362851 ( click the link to review the publication )

Cancer Lett, 2018, 436:28-37

PubMed: 30118842 ( click the link to review the publication )

Cancer Lett, 2015, 357(2):468-75

PubMed: 25444920 ( click the link to review the publication )

J Pathol, 2015, 235(5):672-85

PubMed: ( click the link to review the publication )

FASEB J, 2018, 32(10):5602-5611

PubMed: 29718710 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(1):54-62

PubMed: 29996117 ( click the link to review the publication )

Development, 2013, 140(15):3254-65

PubMed: 23861062 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2450-62

PubMed: 25053822 ( click the link to review the publication )

Mol Oncol, 2013, 8(3):469-82

PubMed: 24444656 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2014, 10.1158/1541-7786.MCR-14-0153-T

PubMed: 25349289 ( click the link to review the publication )

J Immunol, 2014, 192(8):3958-68

PubMed: 24634494 ( click the link to review the publication )
J Lipid Res, 2011, 52(9):1617-25

PubMed: 21757781 ( click the link to review the publication )

J Cell Mol Med, 2015, 10.1111/jcmm.12473

PubMed: 25754106 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(2):372-86

PubMed: 24184209 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1833(3):652-62

PubMed: 23228564 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.03.014

PubMed: 25850000 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2015, 289(46):31950-9

PubMed: 25278019 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(1):125-139

PubMed: 25628925 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Ann Surg Oncol, 2014, 21(1):179-88

PubMed: 23907312 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(10):1555-68

PubMed: 26976639 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )
Acta Pharmacol Sin, 2016, 10.1038/aps.2016.31

PubMed: 27264314 ( click the link to review the publication )

Cell Signal, 2016, 28(8):1086-98

PubMed: 27185187 ( click the link to review the publication )

Mol Brain, 2014, 7:45

PubMed: 24935155 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )

World J Gastroenterol, 2016, 22(18):4501-14

PubMed: 27182160 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):255

PubMed: 25886314 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):241

PubMed: 25884680 ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Transl Oncol, 2014, 10.1016/j.tranon.2014.02.007

PubMed: 24742865 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )
Drug Des Devel Ther, 2015, 9:993-1026

PubMed: 25733817 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87281

PubMed: 24489888 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2013, 8(8): e72053

PubMed: 23991038 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70804

PubMed: 23936469 ( click the link to review the publication )

BMC Biotechnol, 2014, 14:04

PubMed: 24438107 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 454(2):328-34

PubMed: 25450397 ( click the link to review the publication )

Comp Biochem Physiol A , 2014, 168:25-39

PubMed: 24269559 ( click the link to review the publication )

MOL VIS, 2014, 20:1161-1173

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )
Tuberc Respir Dis, 2013, 75(1):9-17

PubMed: 23946753 ( click the link to review the publication )

13 Customer Reviews

Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.
48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.
Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.
Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.
Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h. The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.
Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.
Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Targets

mTOR ^[1]
(HEK293 cells)

~0.1 nM

In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. ^[1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. ^[2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT-29	M4TyS2N6fG:2b4jpZ{BCe3OjeR?=	MoLlNVAhdk1?	M3L0PVczKGh?	Mnv0SG1UVw>?	M17iRXBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=>	M4TCO\|I1QTByOEez
HT-29	NXKySllyS3m2b4TvfIlkKEG\|c3H5	NX30bI5OOTBibl2=	Mny3O\|IhcA>?	NXHFfmtMTE2VTx?=	MVHQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl?	MYeyOFkxODh5Mx?=
HT-29	NFPZe\|BEgXSxdH;4bYMhSXO\|YYm=	MYGxNEBvVQ>?	MWS3NkBp	MVrEUXNQ	NE\JXGJRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	M3\1OVI1QTByOEez
PC3	NXK2UHRRU2mwYYPlJGF{e2G7	MYOxNFAhdk1?	M4XYfVEhcA>?	Mn;zSG1UVw>?	M4rqSXBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u	NHLZTIQzOTl5OE[4Ny=>
PC3	NYfmWlJlU2mwYYPlJGF{e2G7	Mkn5NVAxKG6P	Moj4NUBp	MmraSG1UVw>?	MoWwSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?	MWCyNVk4QDZ6Mx?=
PC3	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\FNFAyNjVizszN	NGHZT2MyKGh?	NYPpcZBSTE2VTx?=	NUXFR2cyUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N	MlW2NlE6Pzh4OEO=
HEK293	MVrGeY5kfGmxbjDBd5NigQ>?	MYGxNFAhdk1?	NF25WZQ5KGh?	NYr4d3YxTE2VTx?=	NVHjb\|k5UW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N	NV6yPXBuOjF3M{mzNFE>
BT-20	M2PyTGtqdmG\|ZTDBd5NigQ>?	NGHGeXUzOCEQvF2=		M4G5SmROW09?	NWDxeFB[TG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:\|cHjvdplt[XSrb36=	M{LCN\|IyOzV\|NUWx
U937	MmS5RY51cWKjY4TldolidCCDc4PhfS=>	NVfIXohzPTBizszN	Mn\EOFghcA>?	M{TBTmROW09?	NGjtbWJKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N\|ch[2WubIO=	MoPENlEyPDJzME[=
U937	Mnu0RY51cWKjY4TldolidCCDc4PhfS=>	MlfqOVAh\|ryP	MV20PEBp	Mn\CSG1UVw>?	MUDEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JG1KWCCycn;0[YlvNWSnZnnjbYVvfCCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJGpTOzJvMjDpckBWQTN5IHPlcIx{	MYiyNVE1OjFyNh?=
U937	MoT5RY51cWKjY4TldolidCCDc4PhfS=>	NGrPTHk2OCEQvF2=	NITUWHQ1QCCq	NWPR[IVpTE2VTx?=	MkKwSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM>	MoDVNlEyPDJzME[=
MCF-7	MnHJRZV1d3CqYXf5JGF{e2G7	NIHTW4g{OCCwTR?=	MUW0JIg>	NG\VRYNFVVOR	NXX2ZYI6UW6mdXPld{BifXSxcHjh[5k>	MkfuNlAxOjhzM{S=
U87MG	MorNT4lv[XOnIFHzd4F6	MoW5NUDPxE1?	NV\zeWllPiCq	MUnEUXNQ	M3;venBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w	NFPmV2gyQTh2OESwOC=>
U87MG	M4PucWtqdmG\|ZTDBd5NigQ>?	M1n4NlEh\|ryP	NFLBe4k3KGh?	NYXaTFJZTE2VTx?=	NWL6V2RUWG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44>	MXuxPVg1QDRyNB?=
U87MG	MXLLbY5ie2ViQYPzZZk>	NGjhWGkyKM7:TR?=	NITpXmk3KGh?	MUPEUXNQ	M4LSNWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w	Mn;JNVk5PDh2MES=
U87MG	MYrLbY5ie2ViQYPzZZk>	MoC5NUDPxE1?	M2O1b\|YhcA>?	NHn6coFFVVOR	M32wV2Rw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN\|cwPDZrIIDoc5NxcG:{eXzheIlwdg>?	MoXUNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb	NH72e2dCfXSxcHjh[5khSXO\|YYm=	MnLpNE4zKM7:TR?=	Mon4NlQhcA>?	NEXvcYFFVVOR	M4nnSmlv\HWlZYOgZZV1d3CqYXf5	MX:xPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3	NHXYd3RCfXSxcHjh[5khSXO\|YYm=	NVTSeWFvOC5{IN88US=>	M{\qSFI1KGh?	NH3URVlFVVOR	MYDJcoR2[2W\|IHH1eI9xcGGpeR?=	Mo\hNVg{QTF7NEm=
H4	M37tPGZ2dmO2aX;uJGF{e2G7	NWmwXHdUOC5{IN88US=>	NIXDTGgzPCCq	NHf5eGFFVVOR	NVfKPZJzUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>?	MU[xPFAzPDV6NB?=
HeLa	M4PWPWZ2dmO2aX;uJGF{e2G7	MVixNFAhdk1?	MV2zOkBp	MVTEUXNQ	NETx[5pKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v	M1PjVFE4PTZ\|M{i1
HeLa	NGHRcJVHfW6ldHnvckBCe3OjeR?=	M4fEflExOCCwTR?=	M17EW\|M3KGh?	MUDEUXNQ	NYLzcVBNUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w	Ml7INVc2PjN\|OEW=
HeLa	M4nocWZ2dmO2aX;uJGF{e2G7	Ml3XNVAxKG6P	MXGzOkBp	MYjEUXNQ	M2fheGlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=>	NHXSUVgyPzV4M{O4OS=>
SYF	MmLaSpVv[3Srb36gRZN{[Xl?	NWjKbVVGOTByIH7N	MmrlNlQhcA>?	NILkUHdFVVOR	NW\a[Fl1UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v	MoXzNVc2PjN\|OEW=
SYF	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\jOYEyODBibl2=	MomyNlQhcA>?	NGH4RmdFVVOR	M3G1Wmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDTXWYh[2WubIO=	NXvCeZhSOTd3NkOzPFU>
HEK293T	MVnBcpRqfmm{YXygRZN{[Xl?	NXrSe\|hEOSCwTR?=	MVm0JIQ>	M2fuV2ROW09?	NGO3SoNKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=>	NUL1[HYyOTd2OEW1NFE>
HEK293T	NH\weHlCdnSrdnnyZYwhSXO\|YYm=	NHHlN2EyKG6P	NHHvXmQ1KGR?	NFfyRYpFVVOR	NUT4T5hXUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0>	NETmVZIyPzR6NUWwNS=>
PBMC	M3ex[2Z2dmO2aX;uJGF{e2G7	MUexJI5O	NU\tV41MOTRiZB?=	NXTLZmFOTE2VTx?=	MWTS[YR2[2W\|IFPDVlUh\GWwc3n0fS=>	NHfZOYcyPzR6NUWwNS=>
PBMC	M33k[mZ2dmO2aX;uJGF{e2G7	M3v1U\|Ehdk1?	NG\L[IoyPCCm	NFnhdnRFVVOR	MoT3SI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk>	M3zWSFE4PDh3NUCx
HEK293 cells	NEK3VWFMcW6jc3WgRZN{[Xl?	M3LkXlUxKG6P	MmHZOFUhdWmw	NIDhUY1FVVOR	MVPJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O	MoXoNVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc	NF20c2JHfW6ldHnvckBCe3OjeR?=	MVOxNFAhdk1?	NHfMWnI1KGh?	NV;aT5JXTE2VTx?=	MVfJcoR2[2W\|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2\|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=>	NVmy[YVmOTdzMkiyOlI>
Human mixed lymphocyte	NFHK[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXCUXE{PSCwTR?=		NFvRNnlFVVOR	NIPmeGtKSzVyPUGuOkBvVS5?	MlvlNVYyQDV6NkW=
Lewis rat lymph node cells	NYX3O3FjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;ZcFQ2KM7:TR?=		M1\KWmROW09?	M4L0dGlEPTB;Mj62JO69VQ>?	MWOxOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice	NF34UW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{T3XVExKG6P	MVG3NkBp	NFy4VZpFVVOR	MY\Jcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P	NHSxNm4yODB{MUm0PC=>
MRK-nu-1	NUW2cGo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULTXXBKUUN3ME2wMlg1PSCyTR?=	NHj2cYRUSU6JRWK=
OCUB-M	NWOxO2J7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPtTWM2OD13LkK0JJBO	NYfhPJpTW0GQR1XS
SF539	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;kTWM2OD1zMT62JJBO	NFHEOXlUSU6JRWK=
ES4	NEHtR\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnNTWM2OD1{MT61JJBO	MlLHV2FPT0WU
RL95-2	M3XqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfCVol{UUN3ME2xNFcheE1?	NHzoT3RUSU6JRWK=
LC-2-ad	NUSyTHhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;2WHlKSzVyPUSyN{BxVQ>?	M4LRSHNCVkeHUh?=
Daudi	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zseGlEPTB;NEO0JJBO	NHLrdohUSU6JRWK=
NTERA-S-cl-D1	NVG0RZhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XKVGlEPTB;NESzJJBO	MnvmV2FPT0WU
OS-RC-2	NFrUfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LqN2lEPTB;NkWyJJBO	NHTlXopUSU6JRWK=
VA-ES-BJ	M1\yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTd{MzDwUS=>	NVi5UVluW0GQR1XS
GR-ST	M{XHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTh2NjDwUS=>	MonKV2FPT0WU
SW872	MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWe5UIs1UUN3ME24OFYheE1?	NFG3OnNUSU6JRWK=
NOS-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\EN4FKSzVyPUi3NUBxVQ>?	NUTXdoFFW0GQR1XS
MC116	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXSyPZVpUUN3ME25PFUheE1?	NH\RTYlUSU6JRWK=
NCI-H1355	NYjWcIZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjmXndKSzVyPUGuNFEhdk1?	MUjTRW5ITVJ?
RPMI-8226	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DNbmlEPTB;MT6xPUBvVQ>?	MnHuV2FPT0WU
TE-15	MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnUNIJKSzVyPUGuN\|Yhdk1?	MoTRV2FPT0WU
Ramos-2G6-4C10	NVjZZXVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37qXGlEPTB;MT60OkBvVQ>?	NHHmbolUSU6JRWK=
KU812	NIrmTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXETWM2OD1{LkCxJI5O	NX3TUYlmW0GQR1XS
EW-1	NYK4NoxwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJwMUegcm0>	NWXY[m9uW0GQR1XS
KS-1	M4jR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPqSmZKSzVyPUKuOFUhdk1?	Ml\kV2FPT0WU
SK-LMS-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHS3dZBKSzVyPUKuOFkhdk1?	NIDYWmNUSU6JRWK=
TGBC1TKB	NXnQcFY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjhfJdNUUN3ME2yMlY6KG6P	NHXuZoxUSU6JRWK=
TE-6	NE\4UndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nwVGlEPTB;Mj63O{BvVQ>?	M1;lO3NCVkeHUh?=
ETK-1	NXzTPVlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnRVYhKSzVyPUKuPFIhdk1?	NHT0cpJUSU6JRWK=
BE-13	M{m1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LZfmlEPTB;Mj65PUBvVQ>?	MoTUV2FPT0WU
A3-KAW	M3HwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVP5b\|F1UUN3ME2yMlk6KG6P	NWPMNFFTW0GQR1XS
TE-10	NITDZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1n2fWlEPTB;Mz6zJI5O	NFPjN45USU6JRWK=
DOHH-2	M2DvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTNwM{Wgcm0>	Mn2zV2FPT0WU
ES6	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2noUmlEPTB;Mz60N{BvVQ>?	NYrEcGZ3W0GQR1XS
OPM-2	NIG1OmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\q[G5[UUN3ME20MlE2KG6P	NFXUO5VUSU6JRWK=
SH-4	NEPIO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoToTWM2OD12LkO0JI5O	NXX0dFlFW0GQR1XS
NB13	NHjoZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrwTWM2OD12LkO2JI5O	NYnRb2hPW0GQR1XS
HUTU-80	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LLTWlEPTB;ND60NkBvVQ>?	MkO2V2FPT0WU
CCRF-CEM	Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fYW2lEPTB;ND65OEBvVQ>?	MXzTRW5ITVJ?
TGBC24TKB	NX;5PYRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTVwNUGgcm0>	M1WxdXNCVkeHUh?=
697	NUfvXYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;pXWlEPTB;Nj6yPEBvVQ>?	NVe2V2ZoW0GQR1XS
J-RT3-T3-5	NFHmTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrCNJBKSzVyPU[uOFYhdk1?	M1viWnNCVkeHUh?=
KALS-1	M1XZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXKwUZVDUUN3ME22MlU3KG6P	MWPTRW5ITVJ?
no-10	NH;WSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTdwMkmgcm0>	MY\TRW5ITVJ?
SK-NEP-1	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFKxc29KSzVyPUiuO\|khdk1?	M2fveHNCVkeHUh?=
L-540	MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fVW2lEPTB;MUCuOFIhdk1?	MWLTRW5ITVJ?
JiyoyeP-2003	MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTFyLkm0JI5O	MnTMV2FPT0WU
HH	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm[1TWM2OD1zMT6zPUBvVQ>?	NX:1NJNRW0GQR1XS
SR	NIjUWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTFzLkS1JI5O	MnrmV2FPT0WU
QIMR-WIL	M4HoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPWe29KSzVyPUGxMlg2KG6P	MoS5V2FPT0WU
A4-Fuk	M{DveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTF\|LkGyJI5O	MVrTRW5ITVJ?
CESS	M3zwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIixb4tKSzVyPUGzMlE{KG6P	Mn\SV2FPT0WU
KE-37	M2PnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGj6XVlKSzVyPUG2MlA4KG6P	MkHGV2FPT0WU
SK-UT-1	M1LFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXYdldKSzVyPUG2MlgyKG6P	MVLTRW5ITVJ?
SIG-M5	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33iPGlEPTB;MUeuNlUhdk1?	M{DENXNCVkeHUh?=
HT	M2\aZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3tW2VjUUN3ME2xO{43KG6P	MofMV2FPT0WU
DEL	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHFT3BKSzVyPUG3Mlk6KG6P	MlfqV2FPT0WU
SK-PN-DW	NFP2eGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJyLkKzJI5O	NUjITmM6W0GQR1XS
RPMI-8402	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPuXJAxUUN3ME2yNU44PyCwTR?=	NI\1[3FUSU6JRWK=
RPMI-6666	M4PlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTUToZKSzVyPUK0MlQzKG6P	MkLCV2FPT0WU
NCI-H720	M4LhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfmdGdIUUN3ME2yOU41OSCwTR?=	NFz6dnNUSU6JRWK=
EW-16	NIX1S\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIL3S5pKSzVyPUK2Mlg4KG6P	NXHoOoRoW0GQR1XS
BL-70	MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTJ6LkO4JI5O	NGW4RnZUSU6JRWK=
SF126	NVvqV49ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIX1dmlKSzVyPUOwMlM5KG6P	MnSyV2FPT0WU
BC-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPvTWM2OD1\|MT6yOkBvVQ>?	NVXRXm5GW0GQR1XS
MHH-PREB-1	M{fYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7l[3A6UUN3ME2zNk41PCCwTR?=	MUHTRW5ITVJ?
A101D	MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTN{Lk[yJI5O	MlWzV2FPT0WU
NMC-G1	NILVVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjzTFdKSzVyPUOzMlY4KG6P	MmLBV2FPT0WU
LB1047-RCC	MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTN2Lk[5JI5O	MlW3V2FPT0WU
EM-2	NFXndnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHv0[YVKSzVyPUO4MlU{KG6P	MVPTRW5ITVJ?
COLO-684	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfyXnp7UUN3ME2zPU45KG6P	NHfkSXFUSU6JRWK=
Becker	NV3P[4VFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HWOGlEPTB;NEGuNFUhdk1?	NUG2U5BkW0GQR1XS
BL-41	M3jPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlv2TWM2OD12Mz62OkBvVQ>?	Mo\MV2FPT0WU
MDA-MB-134-VI	M2nQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkS2TWM2OD12ND6wNkBvVQ>?	NUDLOVhpW0GQR1XS
L-363	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrMZpRwUUN3ME20OE44OyCwTR?=	MmftV2FPT0WU
ECC4	MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7peGNlUUN3ME20OE44QCCwTR?=	NYTUbJNOW0GQR1XS
A388	NUnuZYtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTR2LkiyJI5O	NU[wVnpjW0GQR1XS
HEL	M3XMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M324cmlEPTB;NEmuO\|khdk1?	M1XhUXNCVkeHUh?=
RKO	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHpTWM2OD13MD6yPUBvVQ>?	NIjHO5RUSU6JRWK=
KINGS-1	M4\YNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jJVmlEPTB;NUGuOVUhdk1?	NV7GfHdoW0GQR1XS
EB-3	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPtSYZDUUN3ME21Nk43PyCwTR?=	MmPWV2FPT0WU
ARH-77	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIf4V2JKSzVyPUWyMlghdk1?	NG[2cnZUSU6JRWK=
GCIY	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTV\|LkS2JI5O	M{L1b3NCVkeHUh?=
NCI-H1304	NV\yNXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTV5LkKyJI5O	M33oNHNCVkeHUh?=
KARPAS-299	M4TINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU[yV2NpUUN3ME22NU45OiCwTR?=	MWnTRW5ITVJ?
IA-LM	M2nvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITLWFdKSzVyPU[4MlE{KG6P	NW\wcpNJW0GQR1XS
GI-1	NWriXVRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPQfJJrUUN3ME23NE4{QSCwTR?=	NUj1fHFRW0GQR1XS
TE-11	NX;B[IJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mny3TWM2OD15Nz6xO{BvVQ>?	M1uyPXNCVkeHUh?=
LS-411N	M{LsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTd5LkW3JI5O	MmS3V2FPT0WU
no-11	NGXEOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTh\|LkK0JI5O	M{HmcXNCVkeHUh?=
MV-4-11	NXS2RmpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTBWHVKSzVyPUizMlc{KG6P	M3rkZXNCVkeHUh?=
BV-173	NFLkRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTh\|Lkm3JI5O	M2HXN3NCVkeHUh?=
CMK	M37vbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnQeFFKSzVyPUi0MlE3KG6P	MU\TRW5ITVJ?
LC4-1	MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnT[oZxUUN3ME24Ok44OiCwTR?=	M3q2ZXNCVkeHUh?=
COR-L279	MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jt[mlEPTB;OEeuNlUhdk1?	MVzTRW5ITVJ?
NCI-H209	NHjD[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TIO2lEPTB;OEeuOFEhdk1?	NFn0U3hUSU6JRWK=
Raji	NH;zNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\o[olKSzVyPUi5MlczKG6P	NIPXd2FUSU6JRWK=
LB996-RCC	M{jjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnn[nBSUUN3ME25N{41OyCwTR?=	NInnbIxUSU6JRWK=
NCI-H526	NIrqcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TnbGlEPTB;OUOuOVkhdk1?	MUDTRW5ITVJ?
KGN	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlv3TWM2OD17Nj6yPUBvVQ>?	M3f6UnNCVkeHUh?=
MOLT-4	MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7CNIxxUUN3ME25Ok44QSCwTR?=	MV\TRW5ITVJ?
PF-382	NFHwVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrYV\|JlUUN3ME25Ok44QSCwTR?=	NFnBcYxUSU6JRWK=
BC-3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjGfYtKSzVyPUm5MlE5KG6P	MmfoV2FPT0WU
KARPAS-422	M{\SXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIji[HRKSzVyPUGwNk4xQSCwTR?=	MkTyV2FPT0WU
SBC-1	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TH[WlEPTB;MUC3Mlc2KG6P	NGj5XG1USU6JRWK=
LC-1F	M2rBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\nTWM2OD1zMEiuNFUhdk1?	M2LBTXNCVkeHUh?=
GB-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHW4WYpKSzVyPUGwPU4xOiCwTR?=	MVXTRW5ITVJ?
SNB75	MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrZWGxQUUN3ME2xNVkvPjlibl2=	M1TUNnNCVkeHUh?=
BB65-RCC	NULnPVZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4C3SmlEPTB;MUG5Mlk{KG6P	MWLTRW5ITVJ?
NCI-N87	NXvTOXFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlflTWM2OD1zMkGuPVghdk1?	MorQV2FPT0WU
IST-MEL1	M37NXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPBTWM2OD1zMkKuN\|ghdk1?	M2nBXXNCVkeHUh?=
HOP-62	NY\TdZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTF{Nj64PUBvVQ>?	MnjrV2FPT0WU
ACN	NVr1[\|c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrae2xKSzVyPUG0Ok44PSCwTR?=	NFPUWIxUSU6JRWK=
DMS-114	NXn5cm5zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfFO4dKSzVyPUG1NE43PyCwTR?=	M4j0VXNCVkeHUh?=
MLMA	NV\k[oRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTF3OT64PEBvVQ>?	NVy5XWJ3W0GQR1XS
HT-144	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoGzTWM2OD1zNkWuOFMhdk1?	MnjZV2FPT0WU
C2BBe1	M3K2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWC0bXk5UUN3ME2xOlcvPzZibl2=	Moq2V2FPT0WU
L-428	M1frd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTF5Nz63JI5O	NXK1[JhIW0GQR1XS
DU-4475	M1nCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTF6Nz62PEBvVQ>?	MVPTRW5ITVJ?
CP67-MEL	M3XiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTF7OT6zPEBvVQ>?	NXnxNm9SW0GQR1XS
MEG-01	NGnkPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofPTWM2OD1{MEGuPVYhdk1?	NEHS[ppUSU6JRWK=
IST-SL2	MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfZN\|JKSzVyPUKwPE43OyCwTR?=	MU\TRW5ITVJ?
ES8	NH3tOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTJ{NT65OEBvVQ>?	M4\DcXNCVkeHUh?=
COLO-800	M4TZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTJ\|NT6yPEBvVQ>?	Mk[wV2FPT0WU
MFH-ino	NXGxfWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTJ\|NT64OEBvVQ>?	MnzKV2FPT0WU
OVCAR-4	NUHkWYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXTNnpWUUN3ME2yN\|cvOjRibl2=	MnLXV2FPT0WU
PSN1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIewbodKSzVyPUK0Nk44OSCwTR?=	MXrTRW5ITVJ?
EW-12	NF;tPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDZTWM2OD1{NEOuNUBvVQ>?	NV3LdG1VW0GQR1XS
HCC1599	NF\BN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnn0TWM2OD1{NkGuOFchdk1?	M1PL[nNCVkeHUh?=
SJSA-1	M2rDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1f6T2lEPTB;MkexMlQ3KG6P	MX;TRW5ITVJ?
ST486	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXpU2dKSzVyPUK5Ok4yPCCwTR?=	NXXXSHQ6W0GQR1XS
NOMO-1	NGDmUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvBdplVUUN3ME2zNFAvOjFibl2=	M1PFeHNCVkeHUh?=
MN-60	NFvHRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjRTWM2OD1\|MEWuN\|Ihdk1?	MmPzV2FPT0WU
HCC1187	NVHrdHpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTNyNz6yOUBvVQ>?	M3;PbXNCVkeHUh?=
SW982	M132bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTNzND63OUBvVQ>?	M1PEWXNCVkeHUh?=
LB647-SCLC	NFfre\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE[1VlBKSzVyPUOyPE44OSCwTR?=	MnjKV2FPT0WU
HC-1	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmD4TWM2OD1\|M{WuOUBvVQ>?	NFTOTVhUSU6JRWK=
EHEB	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlO0TWM2OD1\|M{euOVIhdk1?	MlnmV2FPT0WU
TUR	M4TWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnQdGl4UUN3ME2zOlMvQTVibl2=	NULXUpQ{W0GQR1XS
LU-139	NFP4b4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTN5OD6wNkBvVQ>?	NXq1[nc4W0GQR1XS
NB1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4T1cGlEPTB;M{i0MlQ2KG6P	NIPRdHFUSU6JRWK=
BB30-HNC	M{jqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHQWXJKSzVyPUO4PE4{OiCwTR?=	NE[3SYxUSU6JRWK=
HAL-01	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTN6OT6yOkBvVQ>?	NFH5NmlUSU6JRWK=
K5	NUjTR4Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTRzMT6zO{BvVQ>?	M{[1WHNCVkeHUh?=
MZ2-MEL	Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTRzMz62OEBvVQ>?	Ml:wV2FPT0WU
RXF393	M1TIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTRzNj60OUBvVQ>?	MlfLV2FPT0WU
NCI-H1648	NIjDNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTL[\|Y1UUN3ME20NVcvPTNibl2=	M4DxR3NCVkeHUh?=
TE-12	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPnVmlkUUN3ME20N\|QvOjZibl2=	NYC1OY04W0GQR1XS
EoL-1-	NXTP[G1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlX0TWM2OD12M{euPVghdk1?	NH7KcFRUSU6JRWK=
JAR	NWPUUXhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXGybo1vUUN3ME20N\|gvPjJibl2=	MVPTRW5ITVJ?
DSH1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGi0[m1KSzVyPUS1PE46OSCwTR?=	MnnkV2FPT0WU
NCI-H187	M3fDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTR4Mj64NUBvVQ>?	MYTTRW5ITVJ?
HCE-4	NGC3cpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfyenQ6UUN3ME20O\|cvPjZibl2=	MVPTRW5ITVJ?
8-MG-BA	MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLlTWM2OD13OEGuOVIhdk1?	MUTTRW5ITVJ?
KLE	NX\nUZRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHYWlBPUUN3ME21PFUvOiCwTR?=	M3nOVnNCVkeHUh?=
KNS-42	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;sZ21SUUN3ME21PFYvQDFibl2=	NUDUN\|RoW0GQR1XS
MSTO-211H	NHvndHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjHOJBJUUN3ME22NFkvPzRibl2=	MVLTRW5ITVJ?
GDM-1	NH3Wc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoL2TWM2OD14MUSuNFkhdk1?	NH3pTlRUSU6JRWK=
TE-1	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HseWlEPTB;NkS2MlEzKG6P	NEPKUoZUSU6JRWK=
BT-474	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHHTWM2OD14NEeuNFYhdk1?	NWqzWHpHW0GQR1XS
KARPAS-45	M4O5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWf3foxjUUN3ME22OFcvPiCwTR?=	MljjV2FPT0WU
MOLT-16	NEXhUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfkbYJxUUN3ME22OFcvQTNibl2=	MUPTRW5ITVJ?
KURAMOCHI	NVrhV4hxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M16yZ2lEPTB;NkW3MlUyKG6P	NXz6[GdSW0GQR1XS
K-562	M13SVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\MTWM2OD14NkmuOVEhdk1?	NHXqfWpUSU6JRWK=
EKVX	NWjIRXIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPRTWM2OD14N{KuO\|Ehdk1?	MnTmV2FPT0WU
GAK	MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfZbJBKUUN3ME22O\|UvOyCwTR?=	Mkm4V2FPT0WU
NCI-SNU-5	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTZ7MD6wNUBvVQ>?	M1Tu[XNCVkeHUh?=
NCI-H2126	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvCTWM2OD15Mk[uPFchdk1?	MnTxV2FPT0WU
CTV-1	Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITrUpFKSzVyPUe0OE46KG6P	M4G5S3NCVkeHUh?=
SW962	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnQTWM2OD15NEiuOFQhdk1?	MoLnV2FPT0WU
MONO-MAC-6	NV7XOYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7XS3hKSzVyPUe1Ok46OyCwTR?=	M{i3NnNCVkeHUh?=
NCI-H748	M1fBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTd3OD65PUBvVQ>?	M33kZnNCVkeHUh?=
NCI-H524	MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3hTWM2OD15OECuO\|Mhdk1?	NGTFeldUSU6JRWK=
LS-123	M{TPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjsTWM2OD15OUWuOlkhdk1?	NUfGNVlwW0GQR1XS
NB7	M4XsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXBdJBKSzVyPUixOE4yPCCwTR?=	NHftOWRUSU6JRWK=
LS-1034	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HFfGlEPTB;OEK4Mlk5KG6P	NVnuXYc1W0GQR1XS
TE-5	M{DPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTh6Mz61OkBvVQ>?	NWq0c4lCW0GQR1XS
A704	NFvSWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTh7OT6xOUBvVQ>?	NUPIPZJCW0GQR1XS
TK10	M3\qcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnEVlhPUUN3ME25NVYvODNibl2=	NV;iPFdHW0GQR1XS
NCI-H345	MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTOfFZKSzVyPUm0N{4zOiCwTR?=	NGCyTGtUSU6JRWK=
CGTH-W-1	M3XNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXITWM2OD17NEiuNVMhdk1?	MYLTRW5ITVJ?
NCI-H510A	M{HFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLUTZJsUUN3ME25PFUvOTJibl2=	MkXFV2FPT0WU
NCI-H1963	M2\GXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmriTWM2OD1zLkCzNlkzKM7:TR?=	M4jiWnNCVkeHUh?=
SCC-3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETlTFdKSzVyPUGuNFM1OTRizszN	MmrwV2FPT0WU
EW-11	MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTFwMEi3OFMh\|ryP	NEjPfFRUSU6JRWK=
CPC-N	MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTFwMEi4JO69VQ>?	M2nXV3NCVkeHUh?=
NCI-H1417	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF[x[mNKSzVyPUGuNVIzPiEQvF2=	MWLTRW5ITVJ?
DG-75	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvLTWM2OD1zLkG2Nlg2KM7:TR?=	MmDuV2FPT0WU
HD-MY-Z	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LNcmlEPTB;MT6xOlQyPiEQvF2=	NX2zZoRyW0GQR1XS
ATN-1	M1vLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTFwMk[yNFkh\|ryP	NXHY[2w5W0GQR1XS
KM-H2	NEPGeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HXZWlEPTB;MT6yOlQxQCEQvF2=	MVjTRW5ITVJ?
NCI-H2081	M2Lk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHnPHVrUUN3ME2xMlI3PjN5IN88US=>	MmTCV2FPT0WU
HL-60	M4PDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTFwMk[5OVkh\|ryP	MXXTRW5ITVJ?
DB	M4K5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTtTWM2OD1zLkK3NlQzKM7:TR?=	NFTacpRUSU6JRWK=
NCI-H1522	NFjPfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PwR2lEPTB;MT6yPFg5PyEQvF2=	NEG4VWpUSU6JRWK=
AM-38	NUHROWEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTFwM{C3NkDPxE1?	MWrTRW5ITVJ?
NCI-H446	MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\ZTWM2OD1zLkOyNVIyKM7:TR?=	NFjnWFVUSU6JRWK=
SU-DHL-1	MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjYTWM2OD1zLkOyPFAyKM7:TR?=	NFzte4hUSU6JRWK=
NH-12	NHzFemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLGTWM2OD1zLkO2N\|c1KM7:TR?=	MUPTRW5ITVJ?
DMS-79	MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3lTWM2OD1zLkO2PFY3KM7:TR?=	M1vSTXNCVkeHUh?=
NCI-H716	MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTFwM{i5PFYh\|ryP	MmHUV2FPT0WU
ML-2	Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTPU2pKSzVyPUGuOFE2OjlizszN	NFPLOZhUSU6JRWK=
NB10	M4rsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTFwNE[2N\|Ih\|ryP	MnTJV2FPT0WU
ONS-76	NH7FW\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTFwNUO1Olkh\|ryP	NFzkc5hUSU6JRWK=
LOUCY	NFTsc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTFwNUS2OVch\|ryP	M4\LOXNCVkeHUh?=
SCLC-21H	MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2i2fmlEPTB;MT61PFU5OiEQvF2=	NH3YeFBUSU6JRWK=
TGW	Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTxTWM2OD1zLk[zPVc2KM7:TR?=	M37U[XNCVkeHUh?=
LXF-289	NHjNdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXXVG5qUUN3ME2xMlc{OjZ6IN88US=>	Ml\2V2FPT0WU
BB49-HNC	MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfWNopKSzVyPUGuO\|M2QDZizszN	MX\TRW5ITVJ?
NCI-H747	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkexTWM2OD1zLke1N\|Q3KM7:TR?=	M1nZeHNCVkeHUh?=
LU-165	NGrUT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LxS2lEPTB;MT64OFk5PiEQvF2=	MXHTRW5ITVJ?
OMC-1	NHLxd\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGX5b4FKSzVyPUGuPVUxPjZizszN	NVfSUJBMW0GQR1XS
RCC10RGB	NVXlUm5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXn6[\|ZQUUN3ME2xMlk2QDF5IN88US=>	MlzQV2FPT0WU
SW684	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFwOU[wPVkh\|ryP	MorPV2FPT0WU
TE-8	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTJwMEW1OVkh\|ryP	MV\TRW5ITVJ?
SK-N-DZ	NXjWNnF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nRdWlEPTB;Mj6xN\|I4PCEQvF2=	MljDV2FPT0WU
EVSA-T	MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTqNZoyUUN3ME2yMlE4OzF3IN88US=>	MYjTRW5ITVJ?
KASUMI-1	NUXGTHR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHmVHhKSzVyPUKuNVg5OTVizszN	M{\xeHNCVkeHUh?=
NKM-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXlblFKSzVyPUKuNlU1PzJizszN	NEHRRoxUSU6JRWK=
CAL-148	NYrtOoNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvTTWM2OD1{LkOzOlE1KM7:TR?=	NYG1VWF6W0GQR1XS
NCI-H64	MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTJwM{SyN\|Ih\|ryP	NGnHZ4dUSU6JRWK=
KNS-81-FD	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXUfW5FUUN3ME2yMlM3PjJizszN	MWrTRW5ITVJ?
KM12	NFPsSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHtTWM2OD1{LkSwPFM6KM7:TR?=	NHTRcppUSU6JRWK=
SW954	M3rafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLRWJIyUUN3ME2yMlQ4Pzd7IN88US=>	MW\TRW5ITVJ?
NCI-H1395	NVXVdIRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnHZVlKSzVyPUKuOVI3PDVizszN	NYSy[2FMW0GQR1XS
DJM-1	NFHv[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljOTWM2OD1{Lk[wOlMh\|ryP	NXPPc\|hXW0GQR1XS
COLO-668	M3jUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml23TWM2OD1{LkiyOlk2KM7:TR?=	NF:3PI9USU6JRWK=
NCI-H1436	M3fsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTJwOEW2NVUh\|ryP	MXzTRW5ITVJ?
LB2241-RCC	NVW2WmxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXGTWM2OD1{Lki2PFM6KM7:TR?=	NVTkUmtbW0GQR1XS
GT3TKB	NYr4SHk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33WWWlEPTB;Mj64PVA2PSEQvF2=	M{ixd3NCVkeHUh?=
COLO-824	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTJwOEm3Olgh\|ryP	MmnxV2FPT0WU
ES1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHUTWM2OD1{Lki5PFc6KM7:TR?=	NI[zW45USU6JRWK=
LB771-HNC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rJRWlEPTB;Mj65NFk1PiEQvF2=	MmXvV2FPT0WU
GI-ME-N	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXrXZRKSzVyPUOuNFA6ODRizszN	M2f1bnNCVkeHUh?=
NALM-6	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HOfmlEPTB;Mz6wNFk{OyEQvF2=	NH3rWmZUSU6JRWK=
LU-134-A	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHuTWM2OD1\|LkC1OFI2KM7:TR?=	NVzUNVMxW0GQR1XS
DMS-153	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjRNmtKSzVyPUOuNFU5OjRizszN	NF\wT2ZUSU6JRWK=
MZ1-PC	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvmTWM2OD1\|LkC5NFc5KM7:TR?=	NYHk[lN2W0GQR1XS
NCI-H1155	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmqzTWM2OD1\|LkGxOlEh\|ryP	NGPZUZlUSU6JRWK=
CAS-1	M2TpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;qTWM2OD1\|LkGzO\|A4KM7:TR?=	NXH1ZpAzW0GQR1XS
D-502MG	NXfLU45JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTNwMUSzPUDPxE1?	NWq0VpRNW0GQR1XS
NCI-H2141	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlm0TWM2OD1\|LkG3OFUzKM7:TR?=	NUjTPJNMW0GQR1XS
NB6	M{\0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTNwMUiyOVkh\|ryP	NXXYOZBYW0GQR1XS
NCCIT	NWr2N5o6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTNwMkG4NFkh\|ryP	MmXBV2FPT0WU
NB69	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33UdWlEPTB;Mz6zNVg6OSEQvF2=	M{DhWnNCVkeHUh?=
JVM-2	NYL2TZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfnTWM2OD1\|LkO2OFM{KM7:TR?=	M4nz[nNCVkeHUh?=
K052	NHq3U5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTNwM{e5Olgh\|ryP	NYTCcFNsW0GQR1XS
HCC2157	M3;MWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTNwNUOyNlgh\|ryP	NYXIVGc1W0GQR1XS
KMOE-2	NYG1UYNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTNwNUSyOFIh\|ryP	M4\qTXNCVkeHUh?=
SF268	NIfZV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnxdo5kUUN3ME2zMlcyPTV2IN88US=>	M4TFNHNCVkeHUh?=
CHP-126	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk[5TWM2OD1\|Lke2OFU5KM7:TR?=	M1G5NnNCVkeHUh?=
CP66-MEL	MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrOTnpYUUN3ME2zMlc6ODl2IN88US=>	Ml7FV2FPT0WU
NCI-H69	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\VUlJ{UUN3ME20MlAyQTN4IN88US=>	M2rvd3NCVkeHUh?=
A253	M2Ptdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjHTWM2OD12LkCyNVAyKM7:TR?=	MXrTRW5ITVJ?
NB14	NEDYXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIriSHhKSzVyPUSuNVA1PzlizszN	MXvTRW5ITVJ?
NCI-H1694	NGW5RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfCSVJKSzVyPUSuNVMyOTJizszN	NHLJdllUSU6JRWK=
NCI-H2196	NID3NG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTRwMUexOlkh\|ryP	MkLXV2FPT0WU
TE-9	MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1j5fmlEPTB;ND6xO\|U5OiEQvF2=	NH3LcpRUSU6JRWK=
D-283MED	NGPM[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnOTWM2OD12LkG4PFQh\|ryP	MXvTRW5ITVJ?
OCI-AML2	NEW4UGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\JWmlEPTB;ND6xPVQ5QSEQvF2=	MmPXV2FPT0WU
D-263MG	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnzTWM2OD12LkKyPVYyKM7:TR?=	NFnLRYFUSU6JRWK=
MPP-89	MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmP5TWM2OD12LkK3N\|A1KM7:TR?=	NEjo[FBUSU6JRWK=
LAMA-84	M13Sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTRwM{C0NlEh\|ryP	NHPMS\|NUSU6JRWK=
LB373-MEL-D	NGPpb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nlemlEPTB;ND6zOlc5QSEQvF2=	MVzTRW5ITVJ?
UACC-257	M2TLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zScWlEPTB;ND6zPVU{PCEQvF2=	M2nwd3NCVkeHUh?=
MC-CAR	NXPSc29pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTRwNEO5PUDPxE1?	NFfud45USU6JRWK=
COLO-320-HSR	NWjCe3AyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmmxTWM2OD12LkS0OFI4KM7:TR?=	M1jGPXNCVkeHUh?=
P30-OHK	MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHCOnJKSzVyPUSuOlY2QDFizszN	MkGyV2FPT0WU
UACC-812	MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPweGhKSzVyPUSuOlkyPjFizszN	NFLIN49USU6JRWK=
CTB-1	MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LpeWlEPTB;ND63NVU2PSEQvF2=	NF;MbGtUSU6JRWK=
ALL-PO	M{DOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofMTWM2OD12Lki0NFc4KM7:TR?=	M1TXR3NCVkeHUh?=
SK-MEL-2	NFjUTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LUTmlEPTB;ND64Olk2PSEQvF2=	NIXMUJdUSU6JRWK=
TC-YIK	Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzMTWM2OD12Lkm3PVQzKM7:TR?=	NVjCNWZiW0GQR1XS
NCI-H1882	NU[1N25[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLkTWM2OD13LkCyNFAyKM7:TR?=	M4XFTHNCVkeHUh?=
MHH-CALL-2	M{flfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzSTFFKSzVyPUWuNFUxPDJizszN	MmDZV2FPT0WU
U-87-MG	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTVwMEm0OlYh\|ryP	M{C3R3NCVkeHUh?=
NCI-H1092	M3TGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3L1SWlEPTB;NT6yOlU2PSEQvF2=	NYrkcGZiW0GQR1XS
TE-441-T	NXnzcmo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M363WWlEPTB;NT6yO\|gzKM7:TR?=	M1vuWHNCVkeHUh?=
SK-MEL-1	M4LHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mme0TWM2OD13LkK5NFQ1KM7:TR?=	Mlu5V2FPT0WU
EW-22	NWDPO5ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnn6TWM2OD13LkK5OFY3KM7:TR?=	Mn\KV2FPT0WU
MZ7-mel	M3rtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4W5XmlEPTB;NT60NFY6OSEQvF2=	NWHyUFBLW0GQR1XS
LP-1	M13Nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkC1TWM2OD13LkSxNlkyKM7:TR?=	Mli0V2FPT0WU
NCI-SNU-16	M1v6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3WbY5KSzVyPUWuOlQxPzRizszN	MWLTRW5ITVJ?
LU-65	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTVwN{[zO\|Mh\|ryP	NHTXTGFUSU6JRWK=
CW-2	NWXTPFQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPlTWM2OD13Lki1PVU6KM7:TR?=	NHnhNo1USU6JRWK=
WSU-NHL	NGTZSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHpdVVMUUN3ME21Mlk2OTd2IN88US=>	Mle0V2FPT0WU
IST-MES1	NIDyT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGD2XlNKSzVyPUWuPVU1PDNizszN	NVznN2d5W0GQR1XS
U-266	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3Xsb2lEPTB;NT65PFIxOiEQvF2=	NGrnT3hUSU6JRWK=
TALL-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTZwMUS2PFgh\|ryP	NYP1VIdqW0GQR1XS
Calu-6	MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M334XWlEPTB;Nj6xOVMyPiEQvF2=	M2Xzc3NCVkeHUh?=
MMAC-SF	NXy3VoFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDXTWM2OD14LkG4OVU3KM7:TR?=	M{LHdHNCVkeHUh?=
NCI-H82	NXL4NXJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrWTWM2OD14LkKwOFg6KM7:TR?=	NYDKV3pkW0GQR1XS
RS4-11	NVe4d3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TiZ2lEPTB;Nj6yOVg6PyEQvF2=	MkLQV2FPT0WU
SNU-C2B	NHHwdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{L5SmlEPTB;Nj60NFk3QSEQvF2=	NWDrWXpZW0GQR1XS
BOKU	MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rsVmlEPTB;Nj60O\|U6PyEQvF2=	MkDWV2FPT0WU
C8166	M4rD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LUU2lEPTB;Nj61OVkyOiEQvF2=	MljpV2FPT0WU
D-247MG	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXztWIY1UUN3ME23MlA1OzR5IN88US=>	M37WRnNCVkeHUh?=
EW-18	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVewSm57UUN3ME23MlA4Ojl{IN88US=>	MnPSV2FPT0WU
KG-1	Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTdwNkK3N\|gh\|ryP	NHmzWpFUSU6JRWK=
REH	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfGN\|lKSzVyPUeuOlgyODlizszN	M2ThdXNCVkeHUh?=
U-698-M	NHXtdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDGWY1KSzVyPUeuPFQ{OTVizszN	NGrLfmJUSU6JRWK=
KP-N-RT-BM-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\6dVJKSzVyPUeuPVMxOjlizszN	NWSw[29xW0GQR1XS
MS-1	M2X6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\lTFF{UUN3ME23Mlk3ODRzIN88US=>	NWjaR2pXW0GQR1XS
SNU-C1	NITlTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHZeoFKSzVyPUeuPVgyQTJizszN	NWDicm9DW0GQR1XS
SK-MM-2	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRThwMk[wOlUh\|ryP	NHPQSFNUSU6JRWK=
LAN-6	Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jXd2lEPTB;OD6zNFAxOSEQvF2=	NX3lSXNoW0GQR1XS
NEC8	NGrvUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrnTWM2OD16LkOwOlkyKM7:TR?=	NXTReJhQW0GQR1XS
NCI-H1770	NWfMV3c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLKe\|hKSzVyPUiuN\|gxODJizszN	Ml76V2FPT0WU
D-336MG	NV\pVIxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRThwNECxNVYh\|ryP	NVjTWYw6W0GQR1XS
COLO-829	NInh[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7yOY1KSzVyPUiuOFg5PzlizszN	MnfGV2FPT0WU
LS-513	M2W5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlW3TWM2OD16LkW5OVk6KM7:TR?=	MXHTRW5ITVJ?
YT	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXmTWM2OD16Lk[yOFI4KM7:TR?=	NWe3PIl1W0GQR1XS
EW-24	NILyd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDzTWM2OD16Lke2OVQh\|ryP	MoLJV2FPT0WU
IST-SL1	NUPm[5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LudWlEPTB;OD64OlU1OyEQvF2=	M3;Gd3NCVkeHUh?=
CA46	M4LlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVi0WJRGUUN3ME24Mlk2ODl6IN88US=>	MULTRW5ITVJ?
NCI-H1838	NIjqdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRThwOUi2NFIh\|ryP	MV7TRW5ITVJ?
NCI-H719	NFrNVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTlwMkWyO\|kh\|ryP	NVXTXpFGW0GQR1XS
HCE-T	M4HPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PGPGlEPTB;OT6zNFg2OSEQvF2=	NWfRZnA4W0GQR1XS
A498	NFqzbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILoRpJKSzVyPUmuN\|YyOjRizszN	NFiycXlUSU6JRWK=
LB831-BLC	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\Qd4xNUUN3ME25Mlc3PTJzIN88US=>	NHHMe4NUSU6JRWK=
SKM-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPuR25iUUN3ME25Mlg2QTZ\|IN88US=>	MWTTRW5ITVJ?
THP-1	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3MXmtTUUN3ME25Mlk3QTF6IN88US=>	MmrvV2FPT0WU
SHP-77	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHEN\|ZKSzVyPUGwMlQxPyEQvF2=	M1e5PXNCVkeHUh?=
EW-3	MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HSV2lEPTB;MUCuOlI5QSEQvF2=	MYfTRW5ITVJ?
KY821	M4P4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;yTWM2OD1zMD63OlMh\|ryP	Ml;RV2FPT0WU
NCI-SNU-1	NIDTWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\HTWM2OD1zMT6wNlE4KM7:TR?=	NEHyVXZUSU6JRWK=
HCC2218	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTFzLkO5PFYh\|ryP	MknkV2FPT0WU
IM-9	M{e2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrx[ohKSzVyPUGxMlUyODZizszN	NUfab\|N{W0GQR1XS
NCI-H889	MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;Hb2lEPTB;MUGuOVMyOyEQvF2=	MX7TRW5ITVJ?
HDLM-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDSemxnUUN3ME2xNk41OTV7IN88US=>	NIj0dWpUSU6JRWK=
LB2518-MEL	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYD0WXVUUUN3ME2xNk43QDF3IN88US=>	M33sbHNCVkeHUh?=
NCI-H23	NEXWVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\hZmlEPTB;MUOuNlQzPSEQvF2=	NVj3bWxNW0GQR1XS
NB17	NG\aZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Hl[WlEPTB;MUOuOFU4QSEQvF2=	MXLTRW5ITVJ?
NCI-H322M	M4[yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTF2LkSwOlgh\|ryP	NF\Fc\|lUSU6JRWK=
SUP-T1	Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HteWlEPTB;MUSuOFE{KM7:TR?=	MojVV2FPT0WU
ES3	M1vnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTF3LkC3NFMh\|ryP	MXHTRW5ITVJ?
ES5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTF3LkC3PFch\|ryP	NWHFTVRSW0GQR1XS
NCI-H1650	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLpPHZNUUN3ME2xOU41QTd7IN88US=>	M33HeXNCVkeHUh?=
NCI-H226	M3jzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{ewXmlEPTB;MUWuPFc3QCEQvF2=	M3e3W3NCVkeHUh?=
COR-L88	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIi2cY9KSzVyPUG2MlMyPCEQvF2=	M3n1dnNCVkeHUh?=
SCC-15	NXn5RnRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\jdlRKSzVyPUG2MlM5PjlizszN	MoP1V2FPT0WU
GOTO	NIfaUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4SxbmlEPTB;MU[uOFc6OyEQvF2=	NXu1RmRTW0GQR1XS
SIMA	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HVXWlEPTB;MU[uOFgxOiEQvF2=	NHTC[m9USU6JRWK=
NCI-H1299	M332N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTF5LkG1PVEh\|ryP	M3rjeHNCVkeHUh?=
NCI-H1581	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2T2XGlEPTB;MUeuOFIyQSEQvF2=	MV\TRW5ITVJ?
MHH-NB-11	M4fjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;Vc2lEPTB;MUeuPVY5OyEQvF2=	Mn7UV2FPT0WU
MFM-223	MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3njO2lEPTB;MUiuNFU{QCEQvF2=	NUn6R2pQW0GQR1XS
ES7	MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHubmk{UUN3ME2xPE42PDNzIN88US=>	M2DYXXNCVkeHUh?=
JVM-3	M{PvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIn5eJZKSzVyPUG4MlcyPyEQvF2=	M3[2bnNCVkeHUh?=
RL	NEHsc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLMTWM2OD1{MD6zPFgh\|ryP	M3n5WXNCVkeHUh?=
EC-GI-10	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLsfpNuUUN3ME2yNU4zODRzIN88US=>	M3PUVnNCVkeHUh?=
LNCaP-Clone-FGC	NELVOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{noSGlEPTB;MkGuOlc3QCEQvF2=	NHPiSG1USU6JRWK=
IMR-5	Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3:ybmlEPTB;MkGuPFQ6PCEQvF2=	MWHTRW5ITVJ?
KP-N-YS	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTJzLki3OUDPxE1?	NXL3NFdkW0GQR1XS
Mo-T	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTJ{LkKxPFUh\|ryP	M2TvcHNCVkeHUh?=
NCI-H128	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlewTWM2OD1{Mz61PFU{KM7:TR?=	MVHTRW5ITVJ?
RH-1	NHjje3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTJ\|Lke4OlYh\|ryP	M3LYenNCVkeHUh?=
NCI-H2171	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXGTmRKSzVyPUK0MlI1QDVizszN	NITsOG9USU6JRWK=
RPMI-8866	NEDWXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnuV4JKSzVyPUK2Mlc1OiEQvF2=	MnTFV2FPT0WU
SK-N-FI	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LobGlEPTB;MkeuN\|gyOSEQvF2=	NH7XO\|hUSU6JRWK=
LOXIMVI	NWXCO2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorzTWM2OD1{Nz64NFUyKM7:TR?=	NYnZPVFyW0GQR1XS
P31-FUJ	NEKzS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TWOGlEPTB;M{GuOVM4PCEQvF2=	Mn3XV2FPT0WU
KMS-12-PE	NVXNVFJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnmNVN{UUN3ME20PU42OzB{IN88US=>	NHO0bHZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. ^[4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. ^[5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. ^[6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. ^[7]

Protocol

Kinase Assay: ^[1]	+ Expand Immunoblotting for the mTOR kinase assay: HEK293 cells are plated at 2-2.5×10⁵ cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research: ^[3]	+ Expand Cell lines: U87-MG, T98G, and U373-MG Concentrations: Dissolved in DMSO, final concentrations ~25 μM Incubation Time: 72 hours Method: Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope. (Only for Reference)
Animal Research: ^[7]	+ Expand Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O) Dosages: ~4 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	20 mg/mL (21.87 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Rapamycin (Sirolimus) SDF

Molecular Weight	914.18
Formula	C₅₁H₇₉NO₁₃
CAS No.	53123-88-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	AY 22989，NSC-2260804

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03866681	Not yet recruiting	Paroxysmal Nocturnal Hemoglobinuria	Peking Union Medical College Hospital	April 1 2019	Phase 4
NCT03454724	Not yet recruiting	Coronary Artery Disease	Meril Life Sciences Pvt. Ltd.	April 1 2019	Not Applicable
NCT03877809	Not yet recruiting	Beta-Thalassemia	Rare Partners srl Impresa Sociale\|Università degli Studi di Ferrara	April 1 2019	Phase 2
NCT03866681	Not yet recruiting	Paroxysmal Nocturnal Hemoglobinuria	Peking Union Medical College Hospital	April 1 2019	Phase 4
NCT03454724	Not yet recruiting	Coronary Artery Disease	Meril Life Sciences Pvt. Ltd.	April 1 2019	Not Applicable
NCT03877809	Not yet recruiting	Beta-Thalassemia	Rare Partners srl Impresa Sociale\|Università degli Studi di Ferrara	April 1 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Pan mTOR inhibitor

KU-0063794 : mTORC1 and mTORC2, IC50=~10 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.
Classic mTOR Inhibitor

BEZ235 (NVP-BEZ235, Dactolisib) : Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Related mTOR Products4

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Rapamycin (Sirolimus)

Cited by 73 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Rapamycin (Sirolimus) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Rapamycin (Sirolimus)

Cited by 73 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Rapamycin (Sirolimus) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)